ReCAP

 
 
  • Management of Heart Failure in Patients With Type 2 Diabetes   Dr Deepak Bhatt discusses data from EMPA-KIDNEY, SCORED, and SOLOIST showing benefit from sodium-glucose cotransporter 2 inhibitors in management of patients with heart failure and type 2 diabetes.
  • Best Practices in HR+/HER2- Breast Cancer   Leading oncologists discuss best practices in treatment of HR+/HER2- breast cancer, including use of trastuzumab deruxtecan in metastatic disease and adjuvant abemaciclib in early-stage disease.
  • Improving Outcomes in Mantle Cell Lymphoma   Dr Ann LaCasce from the Dana-Farber Cancer Center reviews new and emerging therapies for patients with relapsed/refractory mantle cell lymphoma, including CAR T-cell therapy and bispecific antibodies.
  • Advanced/Metastatic HER2+ Treatment Options and Rationale   Dr Adam Brufsky discusses recommended frontline therapy and subsequent options for metastatic HER2+ breast cancer, including drugs active against central nervous system and brain metastases.
  • Key Advances in Acute Myeloid Leukemia From ASH 2022   Key data on induction therapy, the optimal duration of venetoclax doublet treatment, and novel menin inhibitors top the acute myeloid leukemia highlights from ASH 2022 chosen by Dr Harry Erba.
  • CD19-Directed CAR-T-Cell Therapy in Relapsed/Refractory BCL   Leading oncologists discuss recent trials examining CAR T-cells as second-line treatment in patients with relapsed/refractory B-cell lymphoma and raise questions on optimal use and patient selection.
  • Optimal Treatment for Active SLE   Drs Joan Merrill and Anca Askanase discuss treatment options for active systemic lupus erythematosus (SLE), including biologics anifrolumab and belimumab, as well as optimal selection and timing of therapy.
  • Treatment Advances in Paroxysmal Nocturnal Hemoglobinuria   Up to 40% of patients with paroxysmal nocturnal hemoglobinuria have inadequate response to C5 inhibition. Dr Catherine Broome discusses current and developing alternatives for clinicians to consider.
  • Targeted Therapies for Triple-Negative Breast Cancer   Drs Tripathy and Yam discuss new therapeutic options that can benefit patients with triple-negative breast cancer, including PD-1 inhibitors, PARP inhibitors, and Trop-2 antibody-drug conjugates.
  • Managing T2D Patients With Cardiorenal-Metabolic Syndrome   Physicians discuss management options for patients with type 2 diabetes who have cardiorenal-metabolic syndrome, including the use of SGLT2 inhibitors and GLP-1 agonists.
  • Optimizing COVID-19 Treatment in Hospitalized Patients   French infectious disease expert Karine Lacombe, MD, PhD, discusses current treatment of patients hospitalized with COVID-19 and the most effective early treatment strategies according to disease severity.
  • Therapeutic Approaches in Advanced Breast Cancer   Dr Susan Domchek, from the University of Pennsylvania, discusses the importance of identifying molecular characteristics of metastatic breast cancers to inform the choice of treatment.
  • GLP-1 RA for Management of T2D and Heart Disease   Glucagon-like 1 receptor agonists are guideline-recommended for patients with type 2 diabetes who have heart disease or are at high risk. Dr Vivian Fonseca explains their benefit and appropriate use
  • Expanded Treatment Options for Lupus Nephritis   Dr Joan Merrill discusses standard of care for patients with lupus nephritis and how recently approved agents belimumab and voclosporin have expanded treatment options for a subset of LN patients.
  • Prevention and Management of Severe Hypoglycemia in T2D   Severe hypoglycemia in T2D can be life-threatening, but new therapeutic options offer improved management. Preventive measures include favoring lowest-risk treatments and continuous glucose monitoring.
  • Chronic Kidney Disease in T2D: Early Diagnosis and Management   The benefit of early testing for kidney function in patients with diabetes and the goals of treatment in patients with CKD is discussed by Dr Joseph Vassalotti of Mount Sinai Hospital.
  • Biomarker Measurements in HFrEF   Dr James Januzzi discusses applications for biomarkers in patients with heart failure with reduced ejection fracture, focusing on B-type natriuretic peptide (BNP), N-terminal proBNP, and troponins.
  • Common Challenges in Treating Chronic Myeloid Leukemia   Tyrosine kinase inhibitors have transformed the prognosis for chronic myeloid leukemia, but challenges such as treatment resistance and TKI intolerance remain and are addressed by Dr Ehab Atallah.
  • Treatment Advances in HR+/HER2- Metastatic Breast Cancer   Treatment updates in HR+/HER2- breast cancer are discussed by Drs Nadia Harbeck and Alessandra Gennari, including overall survival improvements from CDK4/6 inhibitors and antibody-drug conjugates.
  • COVID-19 Booster Immunization   Infectious disease experts from Vanderbilt University share advice for communicating with patients about COVID-19 booster immunization with new bivalent vaccines that target the Omicron variant.